Baseline characteristics
| RFA treatment cohort N=1386 | RFA durability cohort N=1154 | |
| Demographics | ||
| Male gender, n (%) | 1122 (81) | 947 (82) |
| Age, years, mean (±SD) | 65 (10) | 64 (9) |
| BMI, kg/m2, mean (±SD) | 28 (4) | 28 (4) |
| BE history | ||
| Prior fundoplication, n (%) | 23 (2) | 21 (2) |
| Surveillance history, n (%) In years, median (P25–P75) | 892 (64) 4 (2–8) | 759 (66) 3 (0–8) |
| Imaging | ||
| Hiatal hernia, n (%) In cm, mean (±SD) | 1321 (95) 3 (2–4) | 1099 (95) 3 (2–4) |
| Oesophagitis, n (%) | 49 (4) | 38 (3) |
| Stenosis, n (%) | 49 (4) | 42 (4) |
| Circumferential BE, median (P25–P75) | 2 (1–6) | 2 (0–5) |
| Maximum BE, median (P25–P75) | 5 (3–8) | 4 (3–7) |
| Visible lesion, n (%) | 860 (62) | 718 (62) |
| Primary Paris type, n (%) | ||
| 0-Ip/s | 81 (11) | 63 (9) |
| 0-IIa | 490 (69) | 419 (58) |
| 0-IIb | 111 (16) | 90 (13) |
| 0-IIc | 29 (4) | 22 (3) |
| 149 missing | 124 missing | |
| Size, mm, median (P25–P75) | 15 (10–20) | 15 (10–20) |
| Pathology | ||
| Worst overall histology, n (%) | ||
| LGD | 375 (27) | 306 (27) |
| HGD | 422 (30) | 362 (31) |
| LR-EAC | 589 (43) | 486 (42) |
| Treatment | ||
| Endoscopic resection, n (%) | 860 (62) | 718 (62) |
| Cap-based ER, n (%) | 839 (61) | 688 (60) |
| ESD, n (%) | 31 (2) | 20 (2) |
| RFA treatment | ||
| C-RFA, median (P25–P75) | 1 (0–1) | 1 (0–1) |
| F-RFA, median (P25–P75) | 2 (1–2) | 2 (1–2) |
| Total RFA, median (P25–P75) | 2 (1–3) | 2 (1–3) |
| Patients with >2 C-RFA, n (%) | 9 (0.6) | 6 (0.5) |
| Patients with >4 total RFA, n (%) | 57 (4) | 44 (4) |
| Touch-up APC, n (%) | 519 (37) | 462 (40) |
| Touch-up ER, n (%) | 80 (6) | 74 (6) |
| ER for incident lesion, n (%) | 69 (5) | 44 (4) |
APC, argon plasma coagulation; BE, Barrett’s oesophagus; BMI, body mass index; C-RFA, circumferential RFA; EAC, esophageal adenocarcinoma; EMR, endoscopic mucosal resection; ER, endoscopic resection; ESD, endoscopic submucosal dissection; F-RFA, focal RFA; GEJ, gastroesophageal junction; HGD, high-grade dysplasia; LGD, low-grade dysplasia; LR-EAC, Low-risk esophageal adenocarcinoma.